Shopping Cart
Remove All
Your shopping cart is currently empty
LY2562175
🥰Excellent
Catalog No. T15806Cas No. 1103500-20-4
LY2562175 is an effective and selective FXR agonist (EC50: 193 nM).
LY2562175
🥰Excellent
Purity: 99.78%
Catalog No. T15806Cas No. 1103500-20-4
LY2562175 is an effective and selective FXR agonist (EC50: 193 nM).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $106 | In Stock | In Stock | |
| 5 mg | $239 | In Stock | In Stock | |
| 10 mg | $388 | In Stock | In Stock | |
| 25 mg | $778 | In Stock | In Stock | |
| 50 mg | $1,230 | In Stock | In Stock | |
| 100 mg | $1,650 | In Stock | In Stock | |
| 200 mg | $2,230 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $283 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.78%
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
| Description | LY2562175 is an effective and selective FXR agonist (EC50: 193 nM). |
| Targets&IC50 | FXR:(EC50)193 nM |
| In vitro | LY2562175 boosts transcriptional activation of human FXR in a cell-based co-transfection assay (EC50: 193 nM) and it also promotes the recruitment of a peptide from the nuclear receptor interaction domain of the coactivator SRC-1 (a relative EC50: 121 nM). It has 93.5% efficacy as compare to GW4064. |
| In vivo | LY2562175 induces a dose-dependent decrease in serum cholesterol and serum triglycerides. LY2562175(female ZDF rats) treatment, causes a dose-dependent lowering of plasma triglycerides in the fasted and nonfasted states. LY2562175 further lowers fasted and nonfasted plasma triglycerides when administered as a fixed-dose combination with BRL49653. At a dose of 10 mg/kg, the decrease in cholesterol with LY2562175 is 80% below vehicle-treated animals, and the decrease in serum triglycerides is 76% from the control group. The ED50 for serum cholesterol is determined to be 2 and 3.4 mg/kg for serum triglycerides. FPLC fractionation of the lipoproteins shows that LY2562175 treatment causes a reduction in vLDL-C and a dramatic increase in HDL-c in this animal model. |
| Molecular Weight | 540.44 |
| Formula | C28H27Cl2N3O4 |
| Cas No. | 1103500-20-4 |
| Smiles | Cn1cc(C(O)=O)c2ccc(cc12)N1CCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 0.1 mg/mL (insoluble) DMSO: 62.5 mg/mL (115.65 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.7 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy LY2562175 | purchase LY2562175 | LY2562175 cost | order LY2562175 | LY2562175 chemical structure | LY2562175 in vivo | LY2562175 in vitro | LY2562175 formula | LY2562175 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.